Investor Presentaiton

Glaucoma Treatment Overview Traditional medication treatment paradigm is chronic medication use causes eye damage limiting future treatment options. Patients and surgeons are transitioning (1) from medications in favour of minimally invasive glaucoma surgery (MIGS) earlier in the disease state. MIGS are a solution to nonadherence and can offer improved safety profile and better certainty of outcome (1). Advancements in diagnostic technologies support earlier intervention. Nova Eye is a key player in the global MIGS market with its canaloplasty device, iTrack™ Advance. (1) Marketscope 2023 Glaucoma Surgical Device Market Report and Marketscope 2022 Glaucoma Surgical Device Market Report •EEEE Patient adherence to glaucoma medications is poor يع Approx 50% of patients are non-compliant with their medications Approx 50% purposely discontinue their medication(s) within 6 months Nordstrom BL, Friedman DS, Mozaffari E, Quigley H, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4): 598-606 Glaucoma surgical devices are increasingly recognised as a viable alternative to medications - and this is the highest area of focus and return for the patient, the physician and the supplier. nova-eye.com | 9

View entire presentation